Wegovy Constipation: Causes, Relief and When to Act

Wegovy constipation is one of the most commonly reported side effects of semaglutide treatment, affecting a notable proportion of people during the dose-escalation phase. Because Wegovy slows gastric emptying and gut motility as part of its mechanism of action, changes to bowel habits are an expected pharmacological consequence rather than a sign that something has gone wrong. This article explains why constipation occurs, how common it is, what practical steps can relieve it, which accompanying symptoms warrant attention, and when to seek advice from a doctor or pharmacist.

Why does Wegovy cause constipation?

Wegovy causes constipation by activating GLP-1 receptors in the gut, which slows gastric emptying and intestinal transit, making stool harder to pass. Reduced appetite, lower fibre and fluid intake, and decreased physical activity can compound the effect.

Wegovy (semaglutide) causes constipation primarily by slowing the movement of food through the gastrointestinal tract, a direct consequence of its mechanism of action. Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the naturally occurring hormone GLP-1.^[1][3] When GLP-1 receptors in the gut are activated, gastric emptying slows considerably, food moves more slowly through the intestines, and stool can become harder and more difficult to pass.

This slowing of gut motility is an inherent pharmacological property of the GLP-1 receptor agonist class, which includes liraglutide (Saxenda). Tirzepatide (Mounjaro) produces similar gastrointestinal effects but acts differently: it is a dual GIP and GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. The effect on bowel transit tends to be more pronounced at higher doses, which is relevant because Wegovy is initiated at a low dose and escalated gradually over several months up to the maintenance doses of 2.4 mg or, for those who require it, 7.2 mg once weekly, in line with the Wegovy Summary of Product Characteristics (SmPC).

Reduced food and fluid intake can compound the problem. Many people taking Wegovy experience a significant reduction in appetite, which means they may eat and drink less than usual. Lower fibre and fluid intake both contribute independently to constipation. Additionally, some people become less physically active during the early weeks of treatment due to nausea or fatigue, and reduced movement can further slow bowel transit. Understanding these overlapping causes helps in choosing the most effective strategies to manage the symptom.

How common is constipation on Wegovy and does it get better?

Constipation is listed as a common adverse effect in the Wegovy SmPC, occurring in at least 1% but fewer than 10% of users. It is most troublesome during dose escalation and often improves once a stable dose is maintained.

Constipation is one of the most frequently reported gastrointestinal side effects of Wegovy. In the clinical trial programme supporting Wegovy's authorisation by the MHRA, constipation was reported as a common adverse reaction. Under EU and UK SmPC frequency conventions, "very common" means occurring in 1 in 10 or more people (at least 10%), while "common" means occurring in at least 1 in 100 but fewer than 1 in 10 people (at least 1% but less than 10%). Constipation is listed in the Wegovy SmPC (section 4.8) as a common undesirable effect within this range. Readers should check the current Wegovy SmPC or patient information leaflet for the most up-to-date frequency data.

For most people, constipation is most troublesome during the dose-escalation phase, when the dose is being increased every four weeks. As the body adjusts to each new dose level, bowel habits often stabilise. Many individuals find that constipation improves or resolves once they have been on a stable dose for several weeks, though this is not universal and some people continue to experience it throughout treatment.

Constipation on Wegovy is generally mild to moderate in severity. Severe or persistent constipation that does not respond to simple measures is less common but does occur and warrants medical review. The pattern of improvement over time is broadly consistent with what is seen with other GLP-1 receptor agonists. The first few months of treatment are typically when gastrointestinal side effects, including constipation, are at their peak, and gradual dose escalation is specifically designed to reduce their impact. If constipation is significantly affecting quality of life, it is worth discussing with a prescriber before the next scheduled dose increase.

What can I do to relieve constipation while taking Wegovy?

Gradually increasing dietary fibre, drinking six to eight glasses of fluid daily, and taking regular gentle exercise are the recommended first steps. Osmotic laxatives such as macrogol are a reasonable short-term option if lifestyle measures are insufficient.

Several practical measures can help relieve constipation while taking Wegovy, and most people find that a combination of dietary, hydration and lifestyle changes is effective. The following approaches are consistent with NHS guidance on managing constipation:

Increase dietary fibre gradually. Aim to include more:

• Wholegrain bread, oats and brown rice

• Fruit, particularly prunes, pears and kiwi fruit

• Vegetables, pulses and legumes

Introduce fibre slowly to avoid bloating, which can already be a concern on Wegovy.

Stay well hydrated. Drinking adequate water throughout the day softens stool and supports bowel transit. Aim for at least six to eight glasses of fluid daily, prioritising water over caffeinated or sugary drinks. This is particularly important if you are also experiencing nausea, vomiting or diarrhoea, as fluid loss from these can worsen constipation and increase the risk of dehydration.

Keep moving. Regular physical activity, even gentle walking, stimulates gut motility and can meaningfully reduce constipation. This also supports the broader goals of weight management.

Establish a routine. Responding promptly to the urge to open the bowels and setting aside time after meals, when the gastrocolic reflex is naturally active, can help regulate bowel habits.

Consider an over-the-counter laxative if needed. Osmotic laxatives such as macrogol (for example, Movicol) are generally well tolerated and are a reasonable first-line option for short-term use. Stimulant laxatives such as senna may also be appropriate in some cases. A pharmacist can advise on the most suitable choice and on how long to use a laxative before seeking further review. The BNF and NICE Clinical Knowledge Summary on constipation in adults provide further guidance on laxative selection.

If you are accessing Wegovy through an online weight-management service, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed.

Which side effects should I watch for alongside constipation?

Severe, persistent abdominal pain radiating to the back may indicate acute pancreatitis and requires immediate medical attention. Gallbladder problems, nausea, heartburn, and injection site reactions are also commonly reported alongside constipation.

Constipation on Wegovy rarely occurs in isolation, and it is important to be aware of other gastrointestinal and systemic side effects that may occur alongside it. The most commonly reported adverse effects in the Wegovy clinical programme include nausea, vomiting, diarrhoea, abdominal pain and bloating. These often fluctuate, and some people experience alternating constipation and looser stools, particularly during dose escalation.

Abdominal pain deserves particular attention. Persistent or severe abdominal pain, especially if accompanied by nausea and vomiting, can occasionally be a sign of acute pancreatitis. The UK SmPC for Wegovy (sections 4.4 and 4.8) notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[1][6] If you develop severe and persistent abdominal pain that radiates to the back, stop taking Wegovy and seek prompt medical assessment.

Gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have also been reported with GLP-1-based therapies.^[1][13] Symptoms to watch for include pain in the upper right abdomen, fever and yellowing of the skin or eyes (jaundice). If you develop these symptoms, seek medical review promptly.

Other side effects to be aware of include:

• Nausea and vomiting, which are the most common GI effects and tend to peak early in treatment

• Heartburn or reflux, which can worsen with slowed gastric emptying

• Fatigue and reduced appetite, which may contribute indirectly to constipation by reducing food and fluid intake

• Injection site reactions, such as redness, bruising or discomfort at the injection site

For people with pre-existing diabetic eye disease, particularly those with pre-proliferative or proliferative retinopathy, rapid improvement in blood glucose control has been associated with transient worsening of diabetic retinopathy. This is most relevant when Wegovy is used alongside diabetes treatment and should be discussed with a clinician before starting.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[16]mhra.gov.uk.

When should I speak to a doctor or pharmacist about my symptoms?

Seek advice if constipation persists beyond two weeks despite self-care, if you notice blood in your stool, or if significant abdominal pain or bloating develops. Severe abdominal pain or inability to pass stool warrants urgent contact with NHS 111 or A&E.

You should speak to a doctor or pharmacist about constipation on Wegovy if it is persistent, worsening or significantly affecting your daily life, rather than waiting to see if it resolves on its own. Mild constipation that responds to dietary changes and adequate hydration can usually be managed without a formal consultation, but there are specific circumstances where professional advice is needed promptly.

Contact your GP or pharmacist if:

• Constipation has lasted more than two weeks despite self-care measures

• You notice blood in your stool or on the toilet paper

• You experience unexplained weight loss beyond what is expected from Wegovy

• You have significant abdominal bloating, cramping or pain that is not settling

• You are considering a laxative but are unsure which type is appropriate for you

• Constipation is making you reluctant to continue with Wegovy, as your prescriber may be able to adjust the dose escalation schedule

Contact NHS 111 for urgent advice if you develop severe abdominal pain, persistent vomiting preventing you from keeping fluids down, or signs of bowel obstruction such as complete inability to pass stool or wind alongside significant abdominal distension.

Go to A&E or call 999 only if you develop symptoms suggesting a serious emergency, such as sudden severe abdominal pain with collapse or signs of shock.

Pregnancy and breastfeeding are important considerations for anyone of childbearing potential taking Wegovy. The medicine is not recommended during pregnancy or breastfeeding.^[1][3] The Wegovy SmPC (section 4.5) advises that, because semaglutide may reduce the efficacy of oral contraceptives by slowing gastric emptying, women using oral contraceptives should switch to or add a non-oral contraceptive method for four weeks after starting Wegovy and for four weeks after each dose increase. If you become pregnant while taking Wegovy, contact your GP promptly.

Note on the contraception advice: the recommendation above reflects the Wegovy SmPC (section 4.5). If you are taking a different weight-management medicine, check the specific guidance for that product with your prescriber or pharmacist.

Scientific References

1. Wegovy 2.4 mg solution for injection – Summary of Product Characteristics.
2. Semaglutide: a medicine to manage type 2 diabetes or obesity.
3. Wegovy (semaglutide) – EPAR Product Information.
4. Semaglutide | Drugs – BNF – NICE.
5. GLP-1 medicines for weight loss and diabetes: what you need to know.
6. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
7. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
8. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
9. Saxenda (liraglutide) – European Medicines Agency.
10. Liraglutide | Drugs – BNF – NICE.
11. Tirzepatide | Drugs – BNF – NICE.
12. Mounjaro (tirzepatide) – EPAR Product Information.
13. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
14. NG242 Diabetic retinopathy: management and monitoring – evidence review C: effectiveness of intensive treatments to lower blood glucose levels.
15. Constipation | Treatment summaries – BNF – NICE.
16. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
17. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.

Frequently Asked Questions